Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

The Jewish Family Making Billions From The Opioid Crisis

If you’ve ever been to a famous art museum or glanced around a prestigious university, you’ve probably seen a wing or building named after a member of the Sackler family. But many may not know that the family’s fortune comes from selling pharmaceuticals—most notably OxyContin, the addictive painkiller at the center of America’s opioid epidemic.

A new profile in Esquire chronicles the life and business practices of Arthur, Mortimer and Raymond Sackler, three brothers from a Jewish immigrant family who built a medical empire. Their descendants privately own Purdue Pharma, which was instrumental in using lobbying and advanced marketing techniques to convince doctors of the need to manage patients’ pain—and then prescribe OxyContin to manage it.

As OxyContin use ballooned in the 1990s and 2000s, so did addiction. Journalist Christopher Glazek noted that under the direction of Richard Sackler, Raymond’s son, “Purdue responded [to criticism] with symbolic concessions while retaining its volume-driven business model. To prevent addicts from forging prescriptions, the company gave doctors tamper-resistant prescription pads; to mollify pharmacists worried about robberies, Purdue offered to replace, free of charge, any stolen drugs.”

In 2007, Purdue was fined $600 million by the federal government for lying to doctors about the potential for patients to abuse OxyContin. No members of the Sackler family were named in the case.

Contact Aiden Pink at pink@forward.com or on Twitter, @aidenpink

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

—  Rachel Fishman Feddersen, Publisher and CEO

With your support, we’ll be ready for whatever 2025 brings.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version